Business
AGM NOTICE
AGM NOTICE.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 2487H Sareum Holdings PLC 14 November 2018 \n\n\n\n\n(AIM: SAR)\n\n\n14 November 2018\n\n\n\nSareum Holdings plc\n(\"Sareum\" or \"the Company\")\nNotice of AGM and Annual Report & Accounts\nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, has notified its shareholders that its Annual General Meeting (\"AGM\") will take place at 10.00 a.m. on 18 December 2018 at the offices of Citigate Dewe Rogerson, 3 London Wall Buildings, London Wall, London EC2M 5SY. \nOn 13 November 2018, the Company Annual Report and Accounts for the year ended 30 June 2018 was posted to shareholders who requested a hard copy and the notice convening the 2018 AGM was posted to all shareholders. A copy of both documents has been placed on the Company website www.sareum.co.uk.\nFor further information, please contact: \n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser)\n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Nominated Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nCitigate Dewe Rogerson (Media enquiries)\n\n\n \n\n\n\n\nShabnam Bashir/ Mark Swallow/ David Dible\n\n\n020 7638 9571\n\n\n\nNotes for editors: \nSareum is a specialist drug development company delivering targeted small molecule therapeutics, to improve the treatment of cancer and autoimmune disease. The Company generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nSareum's leading clinical-stage programme, SRA737, a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology, is in Phase 2 clinical trials targeting ovarian and other advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.\nSareum is also advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases and cancers. TYK2 and JAK1 have roles in pro-inflammatory responses...